Emlino 25/5, manufactured by ACME Laboratories Ltd., contains 25 mg of empagliflozin and 5 mg of linagliptin. Empagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and lowering blood glucose levels. Linagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, enhancing insulin release and decreasing glucagon secretion in a glucose-dependent manner. Together, these medications help improve glycemic control in patients with type 2 diabetes mellitus.